Tenpoint Therapeutics

Tenpoint Therapeutics is a biotechnology company focused on rejuvenating vision in aging eyes and advancing new approaches to eye care. It develops treatments intended to address unmet needs associated with presbyopia, cataracts, and geographic atrophy, with presbyopia as an initial priority. Presbyopia is the age-related decline in near vision that can make everyday activities such as reading, working, and socializing more difficult. Tenpoint emphasizes functional near vision, duration of effect, and tolerability, aiming to support practical, sustained use in daily life.

The company works with eye care professionals to understand real-world needs and shape its treatment development. Its presbyopia pipeline includes BRIMOCHOL PF, for which the company announced acceptance of a New Drug Application by the U.S. Food and Drug Administration. Tenpoint also shares updates about its pipeline, leadership, and corporate activities with patients, investors, and the eye care community. Through its focus on innovation and collaboration, the company seeks to help redefine treatment options for people experiencing age-related changes in vision.